What are the main financial periods covered in this filing?

This filing covers the unaudited results of operations for the three and six months ended June 30, 2025, and the unaudited financial position as of June 30, 2025.

What types of non-GAAP financial measures does Amgen report?

Amgen reports several non-GAAP measures including non-GAAP earnings per share, non-GAAP operating income, non-GAAP operating margin, non-GAAP tax rate, non-GAAP operating expenses (including cost of sales, R&D, and SG&A), and Free Cash Flow (FCF).

What are the primary reasons Amgen provides non-GAAP financial measures?

Amgen provides non-GAAP measures to offer supplementary information that facilitates additional analysis by investors. They use these measures to enhance the understanding of the financial performance and future prospects of the company's ongoing business activities, by enabling comparisons of operational results across different periods.

What specific costs are excluded from Amgen's non-GAAP financial measures?

Key exclusions from GAAP to calculate non-GAAP measures include acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), costs related to restructuring and cost savings initiatives, gains and losses on equity investments, and certain items associated with legal proceedings.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) has filed an 8-K report on August 5, 2025, furnishing its Second Quarter 2025 earnings press release. The release, dated August 5, 2025, details the company's unaudited financial results for the period ending June 30, 2025, and its financial position as of that date. Investors should note that Amgen, in its reporting, provides both GAAP and a range of non-GAAP financial measures, including non-GAAP earnings per share, operating income, operating margin, tax rate, and operating expenses. The company also reports Free Cash Flow (FCF). Amgen utilizes these non-GAAP measures to offer a more comprehensive view of its ongoing business operations and to facilitate comparisons across periods. Key adjustments from GAAP to non-GAAP figures include acquisition-related expenses (such as amortization and impairment of acquired intangible assets and inventory), costs associated with restructuring and cost savings initiatives, and other miscellaneous items like gains/losses on investments and legal proceeding impacts. These adjustments are made to present a clearer picture of operational performance and allow for better internal evaluation and external comparisons.

Key Highlights

1Amgen announced its unaudited financial results for the second quarter ended June 30, 2025, via an 8-K filing on August 5, 2025.
2The company's press release provides both GAAP and non-GAAP financial measures, including non-GAAP EPS, operating income, and Free Cash Flow (FCF).
3Key non-GAAP adjustments include acquisition-related expenses (amortization of intangibles, etc.) and restructuring/cost savings initiatives.
4Other excluded items from GAAP include gains/losses on investments and certain legal proceeding costs.
5Amgen states its use of non-GAAP measures enhances investor understanding of ongoing business performance and facilitates comparisons.
6The company uses these non-GAAP metrics internally for budgeting, financial planning, and evaluating performance against incentive targets.
7The press release and furnished information are considered 'furnished' and not 'filed' under Section 18 of the Securities Exchange Act.

AMGEN INC 8-K Report, Financial Results (Aug 5, 2025)

Summary

Key Highlights

Frequently Asked Questions